Cargando…

Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors

Metastatic melanoma is one of the most immunogenic malignancies due to its high rate of mutations and neoantigen formation. Response to BRAF inhibitors (BRAFi) may be determined by intratumoral immune activation within melanoma metastases. To evaluate whether CD8+ T cell infiltration and distributio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ziemys, Arturas, Kim, Michelle, Menzies, Alexander M., Wilmott, James S., Long, Georgina V., Scolyer, Richard A., Kwong, Larry, Holder, Ashley, Boland, Genevieve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247820/ https://www.ncbi.nlm.nih.gov/pubmed/32528881 http://dx.doi.org/10.3389/fonc.2020.00757

Ejemplares similares

Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
por: Menzies, A M, et al.
Publicado: (2014)

Lymphatic Transport Efficiency Determines Metastatic Potential of Cutaneous Melanoma
por: Holder, Ashley M., et al.
Publicado: (2020)

Dissecting the Lymphatic System to Predict Melanoma Metastasis
por: Suresh, Rishi, et al.
Publicado: (2020)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

A role of proton transfer in peroxidase-catalyzed process elucidated by substrates docking calculations
por: Kulys, Juozas, et al.
Publicado: (2001)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes
por: Cooper, Zachary A, et al.
Publicado: (2013)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
por: Quek, Camelia, et al.
Publicado: (2021)

Bone Density and Hyperlipidemia: The T-lymphocyte Connection
por: Graham, Lucia S, et al.
Publicado: (2010)

The protein kinase promiscuities in the cancer-preventive mechanisms of NSAIDs
por: Norvaisas, Povilas, et al.
Publicado: (2016)

Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms
por: Aung, Thazin Nwe, et al.
Publicado: (2022)

Epigenetic Changes of EGFR play an important role in BRAF inhibitor Resistant Cutaneous Melanomas
por: Wang, Jinhua, et al.
Publicado: (2014)

Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma
por: Maddison, Kelsey, et al.
Publicado: (2021)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
por: Lee, Hansol, et al.
Publicado: (2021)

Tumor Site-Dependent Transport Properties Determine Nanotherapeutics Delivery and Its Efficacy
por: Kai, Megumi, et al.
Publicado: (2019)

Attenuated Microcirculation in Small Metastatic Tumors in Murine Liver
por: Ziemys, Arturas, et al.
Publicado: (2021)

Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer
por: Lee, H E, et al.
Publicado: (2008)

The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
por: Conway, Jordan W., et al.
Publicado: (2022)

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes
por: Shteinman, Eva R., et al.
Publicado: (2022)

Association between density of tumor-infiltrating lymphocytes and prognoses of patients with gastric cancer
por: Yu, Peng-Cheng, et al.
Publicado: (2018)

Prognostic value of the density of tumor-infiltrating lymphocytes in colorectal cancer liver metastases
por: Wang, En, et al.
Publicado: (2021)

Sustained Administration of Hormones Exploiting Nanoconfined Diffusion through Nanochannel Membranes
por: Geninatti, Thomas, et al.
Publicado: (2015)

Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling
por: Chien, Andy J., et al.
Publicado: (2014)

Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas
por: Silva, Inês Pires da, et al.
Publicado: (2018)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
por: Gide, Tuba N., et al.
Publicado: (2019)

Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600(E/K) mutated malignant melanomas
por: Klein, Sebastian, et al.
Publicado: (2021)

Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer
por: Qin, Miao, et al.
Publicado: (2023)

VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment
por: Zhang, Yuqing, et al.
Publicado: (2021)

Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
por: Takada, Koji, et al.
Publicado: (2022)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression
por: Fassler, Danielle J., et al.
Publicado: (2022)

Contrasting Prognostic Effects of Tumor-Infiltrating Lymphocyte Density in Cardia and Non-cardia Gastric Adenocarcinomas
por: Kim, Hyoung-Il, et al.
Publicado: (2020)

The density of tumor-infiltrating lymphocytes and prognosis in resectable hepatocellular carcinoma: a two-phase study
por: Gao, Fengwei, et al.
Publicado: (2021)

Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer
por: Dai, Danian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3p8tm0pn23ur0bhdini6udvu1u